PPARα: Mechanism of species differences and hepatocarcinogenesis of peroxisome proliferators

Toxicology

Volumn 246, Issue 1, 2008, Pages 2-8

  Gonzalez, Frank J ^a   Shah, Yatrik M ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Fenofibrate; Hepatocellular proliferation; Humanized mice; microRNA; Nuclear receptors; Peroxisome proliferators; PPAR; Wy 14,643

Indexed keywords

CLOFIBRATE; DOXYCYCLINE; FATTY ACID; FENOFIBRATE; FIBRIC ACID DERIVATIVE; GEMCOR; GEMFIBROZIL; GLITAZONE DERIVATIVE; MESSENGER RNA; MICRORNA; PEROXISOME PROLIFERATOR; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PHTHALIC ACID BIS(2 ETHYLHEXYL) ESTER; PIRINIXIC ACID; TRIACYLGLYCEROL; UNCLASSIFIED DRUG; DNA BINDING PROTEIN; MYCBP PROTEIN, MOUSE; PYRIMIDINE DERIVATIVE; TRANSCRIPTION FACTOR;

BIOLOGICAL ACTIVITY; CELL PROLIFERATION; DOWN REGULATION; FATTY ACID METABOLISM; GENE INDUCTION; HUMAN; LET 7C GENE; LIVER CARCINOGENESIS; NONHUMAN; ONCOGENE; ONCOGENE C MYC; PLEIOTROPY; PRIORITY JOURNAL; REVIEW; SPECIES DIFFERENCE; TRIACYLGLYCEROL BLOOD LEVEL; ANIMAL; DNA MICROARRAY; DRUG EFFECT; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; METHODOLOGY; MOUSE; PHYSIOLOGY; TOXIC HEPATITIS;

MUS; RATTUS; RODENTIA;

ANIMALS; CELL PROLIFERATION; DNA-BINDING PROTEINS; GENE EXPRESSION REGULATION, NEOPLASTIC; HEPATITIS, TOXIC; MICE; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PEROXISOME PROLIFERATORS; PPAR ALPHA; PYRIMIDINES; SPECIES SPECIFICITY; TRANSCRIPTION FACTORS;

EID: 40049088000     PISSN: 0300483X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.tox.2007.09.030     Document Type: Review

References (18)

1. P.J. Brown L.W. Stuart K.P. Hurley M.C. Lewis D.A. Winegar J.G. Wilson W.O. Wilkison O.R. Ittoop T.M. Willson Identification of a subtype selective human PPARalpha agonist through parallel-array synthesis Bioorg. Med. Chem. Lett. 11 2001 1225 1227
2. C. Cheung T.E. Akiyama J.M. Ward C.J. Nicol L. Feigenbaum C. Vinson F.J. Gonzalez Diminished hepatocellular proliferation in mice humanized for the nuclear receptor peroxisome proliferator-activated receptor alpha Cancer Res. 64 2004 3849 3854
3. S.L. Cox Tesaglitazar: a promising approach in type 2 diabetes Drugs Today (Barc) 42 2006 139 146
4. B. Desvergne L. Michalik W. Wahli Be fit or be sick: peroxisome proliferator-activated receptors are down the road Mol. Endocrinol. 18 2004 1321 1332
5. C. Fievet J.C. Fruchart B. Staels PPARalpha and PPARgamma dual agonists for the treatment of type 2 diabetes and the metabolic syndrome Curr. Opin. Pharmacol. 6 2006 606 614
6. F.J. Gonzalez J.M. Peters R.C. Cattley Mechanism of action of the non-genotoxic peroxisome proliferators: role of the peroxisome proliferator-activator receptor alpha J. Natl. Cancer Inst. 90 1998 1702 1709
7. I. Issemann S. Green Activation of a member of the steroid hormone receptor superfamily by peroxisome proliferators Nature 347 1990 645 650
8. S.M. Johnson H. Grosshans J. Shingara M. Byrom R. Jarvis A. Cheng E. Labourier K.L. Reinert D. Brown F.J. Slack RAS is regulated by the let-7 microRNA family Cell 120 2005 635 647
9. S.S. Lee T. Pineau J. Drago E.J. Lee J.W. Owens D.L. Kroetz P.M. Fernandez-Salguero H. Westphal F.J. Gonzalez Targeted disruption of the alpha isoform of the peroxisome proliferator-activated receptor gene in mice results in abolishment of the pleiotropic effects of peroxisome proliferators Mol. Cell Biol. 15 1995 3012 3022
10. K. Morimura C. Cheung J.M. Ward J.K. Reddy F.J. Gonzalez Differential susceptibility of mice humanized for peroxisome proliferator-activated receptor alpha to Wy-14,643-induced liver tumorigenesis Carcinogenesis 27 2006 1074 1080
11. C.N. Palmer M.H. Hsu K.J. Griffin J.L. Raucy E.F. Johnson Peroxisome proliferator activated receptor-alpha expression in human liver Mol. Pharmacol. 53 1998 14 22
12. M.A. Peraza A.D. Burdick H.E. Marin F.J. Gonzalez J.M. Peters The toxicology of ligands for peroxisome proliferator-activated receptors (PPAR) Toxicol. Sci. 90 2006 269 295
13. J.M. Peters R.C. Cattley F.J. Gonzalez Role of PPAR alpha in the mechanism of action of the nongenotoxic carcinogen and peroxisome proliferator Wy-14,643 Carcinogenesis 18 1997 2029 2033
14. J.M. Peters C. Cheung F.J. Gonzalez Peroxisome proliferator-activated receptor-alpha and liver cancer: where do we stand? J. Mol. Med. 83 2005 774 785
15. J.K. Reddy D.E. Moody D.L. Azarnoff R.M. Tomarelli Hepatic effects of some [4-chloro-6-(2,3-xylidino)-2-pyrimidinylthio] acetic acid (Wy-14,643) analogs in the mouse Arch. Int. Pharmacodyn. Ther. 225 1977 51 57
16. J.K. Reddy M.S. Rao D.L. Azarnoff S. Sell Mitogenic and carcinogenic effects of a hypolipidemic peroxisome proliferator, [4-chloro-6-(2,3-xylidino)-2-pyrimidinylthio]acetic acid (Wy-14, 643), in rat and mouse liver Cancer Res. 39 1979 152 161
17. Y.M. Shah K. Morimura Q. Yang T. Tanabe M. Takagi F.J. Gonzalez Peroxisome proliferator-activated receptor alpha regulates a microRNA-mediated signaling cascade responsible for hepatocellular proliferation Mol. Cell Biol. 27 2007 4238 4247
18. Yang, Q., Nagano, T., Shah, Y.M., Cheung, C., Ito, S., Gonzalez, F.J. in press. The PPARα-humanized mouse: a model to investigate species differences in liver toxicity mediated by PPARα. Toxicol Sci.